Trial
NCT03920839
INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105)
Phase IWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Incyte Corporation
Collaborators
—
Condition
Advanced and/or Metastatic Solid Tumors
Intervention
Retifanlimab
Why stopped
As of November 4, 2019 the study was halted prematurely and will not resume.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-04-24